Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb 22;18(4):31.
doi: 10.3892/mco.2023.2627. eCollection 2023 Apr.

Immunotherapy in malignant peritoneal mesothelioma (Review)

Sabah Alaklabi  1 , Arya Mariam Roy  1 , Joseph J Skitzki  2 , Renuka Iyer  1
Affiliations
Review

Immunotherapy in malignant peritoneal mesothelioma (Review)

Sabah Alaklabi et al. Mol Clin Oncol. .

Abstract

Over the last decade, there has been a movement in cancer treatment away from cytotoxic therapies toward strategies that enhance the immune system against cancer. Immune checkpoint inhibitors (ICIs) have been incorporated into the treatment regimens for patients with various solid tumors. Mesothelioma trials revealed encouraging efficacy; however, patients with peritoneal mesothelioma are usually excluded, slowing the progress of improving the treatment of this aggressive cancer and compelling oncologist to rely on retrospective studies despite their flaws and limitations. Currently, there is no consensus on the role of ICIs in the treatment of malignant peritoneal mesothelioma (MPeM). The present review discusses data from clinical studies that examined immunotherapy in MPeM and evaluates what is known about the relevance of the tumor microenvironment and clinically validated biomarkers for ICIs efficacy. Furthermore, a proposed strategy for utilizing immunotherapy in treating MPeM is discussed.

Keywords: clinical trials; efficacy; immune checkpoint inhibitors; peritoneal mesothelioma; tumor microenvironment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Husain AN, Colby T, Ordonez N, Krausz T, Attanoos R, Beasley MB, Borczuk AC, Butnor K, Cagle PT, Chirieac LR, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2013;137:647–667. doi: 10.5858/arpa.2012-0214-OA. - DOI - PubMed
    1. Bridda A, Padoan I, Mencarelli R, Frego M. Peritoneal mesothelioma: A review. MedGenMed. 2007;9(32) - PMC - PubMed
    1. Teta MJ, Mink PJ, Lau E, Sceurman BK, Foster ED. US mesothelioma patterns 1973-2002: Indicators of change and insights into background rates. Eur J Cancer Prev. 2008;17:525–534. doi: 10.1097/CEJ.0b013e3282f0c0a2. - DOI - PubMed
    1. Selikoff IJ, Hammond EC, Seidman H. Latency of asbestos disease among insulation workers in the United States and Canada. Cancer. 1980;46:2736–2740. doi: 10.1002/1097-0142(19801215)46:12<2736::aid-cncr2820461233>3.0.co;2-l. - DOI - PubMed
    1. Moolgavkar SH, Meza R, Turim J. Pleural and peritoneal mesotheliomas in SEER: Age effects and temporal trends, 1973-2005. Cancer Causes Control. 2009;20:935–944. doi: 10.1007/s10552-009-9328-9. - DOI - PubMed